Adalimumab therapy for childhood uveitis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17011337.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.
Medical subject headings
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Uveitis